Despite the strategies and programs that have been implemented to bring effective and equitable access to new medicines and ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today, approved Livdelzi (seladelpar), developed by ...

The neuromuscular disease therapeutics market is projected to grow by $13.7B from 2025 to 2029, driven by advancements in AI, ...

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.

Servier and Google Cloud expand their partnership to integrate AI and generative AI in drug R&D, focusing on rare diseases.

The European Medicines Agency (EMA) today revealed that, in 2024, it recommended 114 medicines for marketing authorization.

US health systems and Regeneron Genetics Center launch the Truveta Genome Project, a $320M initiative to sequence up to 10M ...

French pharma major Sanofi's participation at the JP Morgan Healthcare Conference was marked by a comprehensive overview of its position in 2024 and its strategic vision for the future.

Johnson & Johnson has started the submission of an original New Drug Application with the US Food and Drug Administration ...

The US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz), from US pharma major Eli Lilly, for the ...

Japanese firms Veneno Technologies and ASKA Pharmaceutical have entered into a joint research agreement to conduct a drug ...

The UK’s health technology assessor, the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends Agamree (vamorolone) for use in the National Health ...